PortalPublikationenDetection of mostly viral pathogens and high proportion of a...

Detection of mostly viral pathogens and high proportion of antibiotic treatment initiation in hospitalised children with community-acquired pneumonia in Switzerland - baseline findings from the first two years of the KIDS-STEP trial

Standard

Detection of mostly viral pathogens and high proportion of antibiotic treatment initiation in hospitalised children with community-acquired pneumonia in Switzerland - baseline findings from the first two years of the KIDS-STEP trial. / Kohns Vasconcelos, Malte; Meyer Sauteur, Patrick M; Keitel, Kristina; Santoro, Regina; Egli, Adrian; Coslovsky, Michael; Seiler, Michelle; Lurà, Marco; Köhler, Henrik; Loevy, Natasha; Kahlert, Christian R; Heininger, Ulrich; Van den Anker, Johannes; Bielicki, Julia A.

in: SWISS MED WKLY, Jahrgang 153, 40040, 20.02.2023.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kohns Vasconcelos, M, Meyer Sauteur, PM, Keitel, K, Santoro, R, Egli, A, Coslovsky, M, Seiler, M, Lurà, M, Köhler, H, Loevy, N, Kahlert, CR, Heininger, U, Van den Anker, J & Bielicki, JA 2023, 'Detection of mostly viral pathogens and high proportion of antibiotic treatment initiation in hospitalised children with community-acquired pneumonia in Switzerland - baseline findings from the first two years of the KIDS-STEP trial', SWISS MED WKLY, Jg. 153, 40040. https://doi.org/10.57187/smw.2023.40040

APA

Kohns Vasconcelos, M., Meyer Sauteur, P. M., Keitel, K., Santoro, R., Egli, A., Coslovsky, M., Seiler, M., Lurà, M., Köhler, H., Loevy, N., Kahlert, C. R., Heininger, U., Van den Anker, J., & Bielicki, J. A. (2023). Detection of mostly viral pathogens and high proportion of antibiotic treatment initiation in hospitalised children with community-acquired pneumonia in Switzerland - baseline findings from the first two years of the KIDS-STEP trial. SWISS MED WKLY, 153, [40040]. https://doi.org/10.57187/smw.2023.40040

Vancouver

Kohns Vasconcelos M, Meyer Sauteur PM, Keitel K, Santoro R, Egli A, Coslovsky M et al. Detection of mostly viral pathogens and high proportion of antibiotic treatment initiation in hospitalised children with community-acquired pneumonia in Switzerland - baseline findings from the first two years of the KIDS-STEP trial. SWISS MED WKLY. 2023 Feb 20;153. 40040. https://doi.org/10.57187/smw.2023.40040

Bibtex

@article{b4e3c392671449c9b3f5ff26104834f1,
title = "Detection of mostly viral pathogens and high proportion of antibiotic treatment initiation in hospitalised children with community-acquired pneumonia in Switzerland - baseline findings from the first two years of the KIDS-STEP trial",
abstract = "AIMS OF THE STUDY: Globally, since the introduction of conjugate-vaccines against encapsulated bacteria, respiratory viruses have caused most hospitalisations for community-acquired pneumonia. The aim of this study was to describe pathogens detected and their association with clinical findings in Switzerland.METHODS: Baseline data were analysed for all trial participants enrolled between September 2018 and September 2020 into the KIDS-STEP Trial, a randomised controlled superiority trial on the effect of betamethasone on clinical stabilisation of children admitted with community-acquired pneumonia. Data included clinical presentation, antibiotic use and results of pathogen detection. In addition to routine sampling, nasopharyngeal specimens were analysed for respiratory pathogens using a panel polymerase chain reaction test covering 18 viral and 4 bacterial pathogens.RESULTS: 138 children with a median age of 3 years were enrolled at the eight trial sites. Fever (obligatory for enrolment) had been present for median 5 days before admission. Most common symptoms were reduced activity (129, 93.5%) and reduced oral intake (108, 78.3%). Oxygen saturation <92% was found in 43 (31.2%). Forty-three participants (29.0%) were already on antibiotic treatment prior to admission and 104 participants (75.4%) received antibiotic treatment on admission. Pathogen testing results were available from 132 children: 31 (23.5%) had respiratory syncytial virus detected, 21 (15.9%) human metapneumovirus. The pathogens detected showed expected seasonal and age preponderance and were not associated with chest X-ray findings.CONCLUSIONS: In the context of the predominantly viral pathogens detected, the majority of antibiotic treatment is probably unnecessary. The ongoing trial, as well as other studies, will be able to provide comparative pathogen detection data to compare pre- and post-COVID-19-pandemic settings.",
keywords = "Child, Humans, Child, Preschool, COVID-19, Child, Hospitalized, Switzerland, Pneumonia, Hospitalization, Community-Acquired Infections/drug therapy",
author = "{Kohns Vasconcelos}, Malte and {Meyer Sauteur}, {Patrick M} and Kristina Keitel and Regina Santoro and Adrian Egli and Michael Coslovsky and Michelle Seiler and Marco Lur{\`a} and Henrik K{\"o}hler and Natasha Loevy and Kahlert, {Christian R} and Ulrich Heininger and {Van den Anker}, Johannes and Bielicki, {Julia A}",
year = "2023",
month = feb,
day = "20",
doi = "10.57187/smw.2023.40040",
language = "English",
volume = "153",
journal = "SWISS MED WKLY",
issn = "1424-7860",
publisher = "EMH Swiss Medical Publishers Ltd.",

}

RIS

TY - JOUR

T1 - Detection of mostly viral pathogens and high proportion of antibiotic treatment initiation in hospitalised children with community-acquired pneumonia in Switzerland - baseline findings from the first two years of the KIDS-STEP trial

AU - Kohns Vasconcelos, Malte

AU - Meyer Sauteur, Patrick M

AU - Keitel, Kristina

AU - Santoro, Regina

AU - Egli, Adrian

AU - Coslovsky, Michael

AU - Seiler, Michelle

AU - Lurà, Marco

AU - Köhler, Henrik

AU - Loevy, Natasha

AU - Kahlert, Christian R

AU - Heininger, Ulrich

AU - Van den Anker, Johannes

AU - Bielicki, Julia A

PY - 2023/2/20

Y1 - 2023/2/20

N2 - AIMS OF THE STUDY: Globally, since the introduction of conjugate-vaccines against encapsulated bacteria, respiratory viruses have caused most hospitalisations for community-acquired pneumonia. The aim of this study was to describe pathogens detected and their association with clinical findings in Switzerland.METHODS: Baseline data were analysed for all trial participants enrolled between September 2018 and September 2020 into the KIDS-STEP Trial, a randomised controlled superiority trial on the effect of betamethasone on clinical stabilisation of children admitted with community-acquired pneumonia. Data included clinical presentation, antibiotic use and results of pathogen detection. In addition to routine sampling, nasopharyngeal specimens were analysed for respiratory pathogens using a panel polymerase chain reaction test covering 18 viral and 4 bacterial pathogens.RESULTS: 138 children with a median age of 3 years were enrolled at the eight trial sites. Fever (obligatory for enrolment) had been present for median 5 days before admission. Most common symptoms were reduced activity (129, 93.5%) and reduced oral intake (108, 78.3%). Oxygen saturation <92% was found in 43 (31.2%). Forty-three participants (29.0%) were already on antibiotic treatment prior to admission and 104 participants (75.4%) received antibiotic treatment on admission. Pathogen testing results were available from 132 children: 31 (23.5%) had respiratory syncytial virus detected, 21 (15.9%) human metapneumovirus. The pathogens detected showed expected seasonal and age preponderance and were not associated with chest X-ray findings.CONCLUSIONS: In the context of the predominantly viral pathogens detected, the majority of antibiotic treatment is probably unnecessary. The ongoing trial, as well as other studies, will be able to provide comparative pathogen detection data to compare pre- and post-COVID-19-pandemic settings.

AB - AIMS OF THE STUDY: Globally, since the introduction of conjugate-vaccines against encapsulated bacteria, respiratory viruses have caused most hospitalisations for community-acquired pneumonia. The aim of this study was to describe pathogens detected and their association with clinical findings in Switzerland.METHODS: Baseline data were analysed for all trial participants enrolled between September 2018 and September 2020 into the KIDS-STEP Trial, a randomised controlled superiority trial on the effect of betamethasone on clinical stabilisation of children admitted with community-acquired pneumonia. Data included clinical presentation, antibiotic use and results of pathogen detection. In addition to routine sampling, nasopharyngeal specimens were analysed for respiratory pathogens using a panel polymerase chain reaction test covering 18 viral and 4 bacterial pathogens.RESULTS: 138 children with a median age of 3 years were enrolled at the eight trial sites. Fever (obligatory for enrolment) had been present for median 5 days before admission. Most common symptoms were reduced activity (129, 93.5%) and reduced oral intake (108, 78.3%). Oxygen saturation <92% was found in 43 (31.2%). Forty-three participants (29.0%) were already on antibiotic treatment prior to admission and 104 participants (75.4%) received antibiotic treatment on admission. Pathogen testing results were available from 132 children: 31 (23.5%) had respiratory syncytial virus detected, 21 (15.9%) human metapneumovirus. The pathogens detected showed expected seasonal and age preponderance and were not associated with chest X-ray findings.CONCLUSIONS: In the context of the predominantly viral pathogens detected, the majority of antibiotic treatment is probably unnecessary. The ongoing trial, as well as other studies, will be able to provide comparative pathogen detection data to compare pre- and post-COVID-19-pandemic settings.

KW - Child

KW - Humans

KW - Child, Preschool

KW - COVID-19

KW - Child, Hospitalized

KW - Switzerland

KW - Pneumonia

KW - Hospitalization

KW - Community-Acquired Infections/drug therapy

U2 - 10.57187/smw.2023.40040

DO - 10.57187/smw.2023.40040

M3 - SCORING: Journal article

C2 - 36800889

VL - 153

JO - SWISS MED WKLY

JF - SWISS MED WKLY

SN - 1424-7860

M1 - 40040

ER -